Announcements
Diagnostics enable the detection of the monkeypox virus in humans Excerpt from the Press Release: SAN DIEGO, Aug. 18, 2022 /PRNewswire/ — CorDx, a global leader in the development, manufacturing, and distribution of diagnostics and medical devices, was recently granted a CE Mark certificate for two of the company’s monkeypox diagnostic tests. The CE Mark,…
Read More
New clinical data demonstrate high and sustained geometric mean fold rises (GMFR) in neutralizing antibodies against all evaluated Omicron variants Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, “Arcturus Therapeutics”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and…
Read More
First in human study demonstrates positive safety and tolerability profile for MapLight’s M1/M4 muscarinic agonist therapy Excerpt from the Press Release: SAN FRANCISCO, Aug. 18, 2022 /PRNewswire/ — MapLight Therapeutics today announced it has completed its Phase 1 clinical trial evaluating ML-007, the second clinical compound developed using the MapLight platform. ML-007 is an M1/M4…
Read More
Excerpt from the Press Release: SAN FRANCISCO and SUZHOU, China, Aug. 17, 2022 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first healthy volunteer has been successfully dosed in…
Read More
Excerpt from the Press Release: Valo’s Opal Computational Platform™ being used to select a patient subset within non-proliferative diabetic retinopathy patients at high risk of progressing toward vision-threatening disease BOSTON, Aug. 18, 2022 /PRNewswire/ — Valo Health, Inc. (“Valo”), the technology company focused on transforming the drug discovery and development process using human-centric data and…
Read More
SpIntellx, Inc., a leader in spatially intelligent biology, and iCura Diagnostics, a leading contract research organization (CRO) focused on capitalizing multiomic data to accelerate end-to-end clinical workflow solutions and biomarker discovery, today announced a partnership to transform precision oncology through unlocking the power of genomic, proteomics, and transcriptomic data using advanced spatial analytics. Excerpt from…
Read More
Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in…
Read More
First round of Innovation to Implementation Supplement (I2IS) grants awarded to five promising research projects taking unique approaches to addressing cancer. Excerpt from the Press Release: August 11, 2022, TORONTO – Five Ontario-based research projects will take the next step toward advancing cancer care in the province thanks to funding from the Ontario Institute for…
Read More
BEACON study will evaluate bitopertin as a potential disease-modifying treatment for patients with Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP) Key assessments include changes in protoporphyrin IX levels, safety, tolerability and measures of photosensitivity; preliminary data expected by 1H 2023 Excerpt from the Press Release: WATERTOWN, Mass., Aug. 10, 2022 /PRNewswire/ — Disc Medicine, a clinical-stage biotechnology…
Read More
The first-of-its-kind, CRISPR-based therapeutic aims to stop the progression of Duchenne muscular dystrophy in a single-patient dosing Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Cure Rare Disease (CRD) – a Boston-based 501c3 nonprofit biotech – announces the approval from the U.S. Food and Drug Administration (FDA) to administer its very first therapeutic. The drug, named CRD-TMH-001, treats…
Read More